Reclast granted broadened indication
FDA gives once-yearly zoledronic acid injection expanded use.
The Food & Drug Administration has broadened the indication for zoledronic acid (Reclast, Novartis) to include the prevention of fractures in patients who’ve had a recent hip fracture. The decision was based on safety and efficacy data from the Recurrent Fracture Trial that showed an increase in bone mineral density and a 35% reduction in risk of new fractures in patients treated with the drug compared with placebo. According to the manufacturer, Reclast is given as a once-yearly 15-minute intravenous infusion and, when taken along with calcium and vitamin D supplements, helps to protect against fracture for a full year.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
